HC Wainwright & Co. Reiterates Buy Rating on Phathom Pharmaceuticals, Inc. (PHAT)

Market Context

Phathom Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $9.03 with a market capitalization of $1.0B. The stock has gained 32.3% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Phathom Pharmaceuticals, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Phathom Pharmaceuticals, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 31, 2026	HC Wainwright & Co.	Buy	N/A
Jul 30, 2026	Needham	Buy	N/A
Jun 17, 2026	HC Wainwright & Co.	Buy	N/A
Mar 27, 2026	Barclays	Overweight	N/A
Feb 27, 2026	Guggenheim	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View PHAT Stock Page